Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes

Teplizumab (Tzield, Sanofi) is indicated to 'delay the onset of Stage 3 type 1 diabetes in adult and paediatric patients 8 years of age and older with Stage 2 type 1 diabetes (T1D)'.

The dosage schedule is available in the summary of product characteristics for teplizumab.

The list price of teplizumab is £10,939.12 for a 2‑mg vial (excluding VAT, BNF online, accessed May 2026).

The company has a commercial arrangement. This makes teplizumab available to the NHS with a discount. The size of the discount is commercial in confidence.

For information, the Carbon Reduction Plan for UK carbon emissions is published on Sanofi's webpage on environmental impact.